Published in Genes Dev on September 15, 2009
Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med (2011) 4.91
The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer? EMBO Rep (2010) 4.05
MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer (2011) 3.91
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med (2011) 3.82
Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev (2009) 3.58
Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell (2010) 3.53
Large non-coding RNAs: missing links in cancer? Hum Mol Genet (2010) 3.49
MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell (2013) 2.92
miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med (2011) 1.94
The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol Ther (2010) 1.89
Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res (2011) 1.80
MicroRNAs and metastasis: little RNAs go a long way. Cancer Res (2010) 1.73
Epigenetic modifications in cancer. Clin Genet (2011) 1.53
MiR-200, a new star miRNA in human cancer. Cancer Lett (2013) 1.50
Accuracy of microRNAs as markers for the detection of neck lymph node metastases in patients with head and neck squamous cell carcinoma. BMC Med (2015) 1.49
MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Mol Cell Biol (2011) 1.49
MicroRNAs expression profiling of eutopic proliferative endometrium in women with ovarian endometriosis. Reprod Biol Endocrinol (2013) 1.45
Role of microRNA-26b in glioma development and its mediated regulation on EphA2. PLoS One (2011) 1.33
Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One (2012) 1.32
The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochim Biophys Acta (2010) 1.29
The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta (2012) 1.26
The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells. Int J Oncol (2013) 1.25
Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One (2013) 1.23
The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. Cancer Microenviron (2010) 1.21
Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One (2012) 1.18
Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Cancer Res (2014) 1.16
Comparative mRNA and microRNA expression profiling of three genitourinary cancers reveals common hallmarks and cancer-specific molecular events. PLoS One (2011) 1.15
Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. J Biol Chem (2011) 1.14
Our changing view of the genomic landscape of cancer. J Pathol (2010) 1.13
Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther (2014) 1.12
Snail and the microRNA-200 family act in opposition to regulate epithelial-to-mesenchymal transition and germ layer fate restriction in differentiating ESCs. Stem Cells (2011) 1.11
Identification of responsive gene modules by network-based gene clustering and extending: application to inflammation and angiogenesis. BMC Syst Biol (2010) 1.09
Cellular microRNAs 200b and 429 regulate the Epstein-Barr virus switch between latency and lytic replication. J Virol (2010) 1.09
The role of microRNAs in ovarian cancer initiation and progression. J Cell Mol Med (2010) 1.08
MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS One (2012) 1.07
Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol (2013) 1.06
MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines. Cancer Biol Ther (2014) 1.04
Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility. Oncogene (2012) 1.03
The roles of microRNAs in tumorigenesis and angiogenesis. Int J Physiol Pathophysiol Pharmacol (2010) 1.03
MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther (2013) 1.01
MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications. Cancer Lett (2009) 1.01
Current knowledge on pancreatic cancer. Front Oncol (2012) 1.01
MicroRNA regulation of tumorigenesis, cancer progression and interpatient heterogeneity: towards clinical use. Genome Biol (2014) 0.99
MicroRNAs in pancreatic malignancy: progress and promises. Cancer Lett (2014) 0.98
Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. J Oncol (2010) 0.97
GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Sci Rep (2015) 0.97
Genetic deletion of the desmosomal component desmoplakin promotes tumor microinvasion in a mouse model of pancreatic neuroendocrine carcinogenesis. PLoS Genet (2010) 0.96
miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression. Oncogene (2011) 0.96
MicroRNAs overexpressed in ovarian ALDH1-positive cells are associated with chemoresistance. J Ovarian Res (2013) 0.95
MiR-125b acts as an oncogene in glioblastoma cells and inhibits cell apoptosis through p53 and p38MAPK-independent pathways. Br J Cancer (2013) 0.95
The two most common histological subtypes of malignant germ cell tumour are distinguished by global microRNA profiles, associated with differential transcription factor expression. Mol Cancer (2010) 0.94
Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic properties. Cell Cycle (2013) 0.94
The proto-oncogene KRAS is targeted by miR-200c. Oncotarget (2014) 0.93
MicroRNA theragnostics for the clinical management of multiple myeloma. Leukemia (2013) 0.93
Epigenetics and cancer. J Appl Physiol (1985) (2010) 0.93
Functional Role of the microRNA-200 Family in Breast Morphogenesis and Neoplasia. Genes (Basel) (2014) 0.92
MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia (2012) 0.92
CDC25A targeting by miR-483-3p decreases CCND-CDK4/6 assembly and contributes to cell cycle arrest. Cell Death Differ (2013) 0.91
Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. Sci Rep (2013) 0.91
Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer. Cancer Metastasis Rev (2010) 0.90
Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review. Int J Hepatol (2011) 0.90
Targeting microRNAs as key modulators of tumor immune response. J Exp Clin Cancer Res (2016) 0.89
Loss of p19(Arf) facilitates the angiogenic switch and tumor initiation in a multi-stage cancer model via p53-dependent and independent mechanisms. PLoS One (2010) 0.88
Circulating MicroRNA as Biomarkers: An Update in Prostate Cancer. Mol Cell Pharmacol (2011) 0.86
Patterns of microRNA expression in non-human primate cells correlate with neoplastic development in vitro. PLoS One (2010) 0.85
A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. Cancer Discov (2015) 0.85
MicroRNA regulation in cancer-associated fibroblasts. Cancer Immunol Immunother (2011) 0.84
Sequential inductions of the ZEB1 transcription factor caused by mutation of Rb and then Ras proteins are required for tumor initiation and progression. J Biol Chem (2013) 0.84
Targeting CSC-related miRNAs for cancer therapy by natural agents. Curr Drug Targets (2012) 0.83
Targeting CSCs in tumor microenvironment: the potential role of ROS-associated miRNAs in tumor aggressiveness. Curr Stem Cell Res Ther (2014) 0.81
Overexpression of miR-483-5p/3p cooperate to inhibit mouse liver fibrosis by suppressing the TGF-β stimulated HSCs in transgenic mice. J Cell Mol Med (2014) 0.81
Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer. Pancreas (2013) 0.81
Essential role of miRNAs in orchestrating the biology of the tumor microenvironment. Mol Cancer (2016) 0.80
Selective inhibition of miR-21 by phage display screened peptide. Nucleic Acids Res (2015) 0.79
MicroRNA polymorphisms and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev (2014) 0.79
Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes. Pharmaceuticals (Basel) (2013) 0.78
Sequential Salinomycin Treatment Results in Resistance Formation through Clonal Selection of Epithelial-Like Tumor Cells. Transl Oncol (2014) 0.78
Antioxidant Mechanisms and ROS-Related MicroRNAs in Cancer Stem Cells. Oxid Med Cell Longev (2015) 0.78
The transcriptome of lung tumor-infiltrating dendritic cells reveals a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outcome. Oncoimmunology (2016) 0.78
Low MiR-149 expression is associated with unfavorable prognosis and enhanced Akt/mTOR signaling in glioma. Int J Clin Exp Pathol (2015) 0.77
Identification and characterization of poorly differentiated invasive carcinomas in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS One (2013) 0.77
Molecular and Genetic Predictors of Breast-to-Brain Metastasis: Review and Case Presentation. Cureus (2015) 0.77
Cancer: evolutionary, genetic and epigenetic aspects. Clin Epigenetics (2010) 0.77
miRNAs As Diagnostic and Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions: A Review. Biomark Insights (2015) 0.76
Prospects of miRNA-based therapy for pancreatic cancer. Curr Drug Targets (2013) 0.76
A step-by-step microRNA guide to cancer development and metastasis. Cell Oncol (Dordr) (2017) 0.75
Role of STAT3 and FOXO1 in the Divergent Therapeutic Responses of Non-metastatic and Metastatic Bladder Cancer Cells to miR-145. Mol Cancer Ther (2017) 0.75
Degradable Cross-Linked Nanoassemblies as Drug Carriers for Heat Shock Protein 90 Inhibitor 17-N-Allylamino-17-demethoxy-geldanamycin. Pharmaceuticals (Basel) (2011) 0.75
MicroRNA-200 Family Profile: A Promising Ancillary Tool for Accurate Cancer Diagnosis. Am J Ther (2016) 0.75
miR-21 and KLF4 jointly augment epithelial‑mesenchymal transition via the Akt/ERK1/2 pathway. Int J Oncol (2017) 0.75
MicroRNA dysregulation in the tumor microenvironment influences the phenotype of pancreatic cancer. Mod Pathol (2017) 0.75
Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Semin Liver Dis (2017) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
The hallmarks of cancer. Cell (2000) 113.05
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
The functions of animal microRNAs. Nature (2004) 64.85
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol (2008) 24.27
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A (2006) 21.58
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res (2005) 18.58
Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res (2003) 17.13
Requirement of bic/microRNA-155 for normal immune function. Science (2007) 16.24
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
The diverse functions of microRNAs in animal development and disease. Dev Cell (2006) 15.62
MicroRNA expression in zebrafish embryonic development. Science (2005) 15.52
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev (2008) 15.01
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 14.59
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell (2009) 13.09
Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A (2005) 12.96
Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell (2008) 12.29
Regulation of the germinal center response by microRNA-155. Science (2007) 12.25
MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A (2007) 11.42
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep (2008) 10.71
Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A (2006) 10.65
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA (2007) 9.97
miR-21-mediated tumor growth. Oncogene (2006) 9.90
Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature (1985) 9.78
A progression puzzle. Nature (2002) 9.56
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A (2005) 8.60
A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature (1998) 8.48
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology (2008) 8.10
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell (2008) 7.56
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun (2005) 7.50
Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature (1989) 7.30
The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell (2008) 7.26
A microRNA signature of hypoxia. Mol Cell Biol (2006) 7.24
Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A (2008) 6.89
MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem (2007) 6.88
Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene (2006) 6.61
miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell (2008) 6.59
Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer (2007) 6.57
The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev (1992) 5.73
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol (2006) 5.40
Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet (2001) 4.96
The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle (2008) 4.95
Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem (2006) 4.57
Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A (2006) 4.51
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene (2007) 4.46
Asymmetric regulation of imprinting on the maternal and paternal chromosomes at the Dlk1-Gtl2 imprinted cluster on mouse chromosome 12. Nat Genet (2003) 4.25
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia (2001) 4.22
MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer (2006) 4.11
The conserved microRNA miR-8 tunes atrophin levels to prevent neurodegeneration in Drosophila. Cell (2007) 4.00
The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell (2003) 3.89
MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell (2008) 3.84
Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev (2009) 3.58
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol (2004) 3.40
An optimized isolation and labeling platform for accurate microRNA expression profiling. RNA (2005) 3.12
Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell (2002) 3.02
A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature (1994) 2.51
Members of the miRNA-200 family regulate olfactory neurogenesis. Neuron (2008) 2.07
Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer (1996) 1.92
Dissecting multistep tumorigenesis in transgenic mice. Annu Rev Genet (1988) 1.79
VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol (2008) 1.77
The microRNA miR-8 is a conserved negative regulator of Wnt signaling. Proc Natl Acad Sci U S A (2008) 1.76
Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma. Cancer Res (1995) 1.47
Proliferation, senescence, and neoplastic progression of beta cells in hyperplasic pancreatic islets. Cell (1988) 1.02
Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis. Oncogene (2005) 1.02
Integrative oncogenomic approaches for accelerated cancer-gene discovery. Curr Opin Oncol (2008) 0.91
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature (2005) 31.60
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36
SOAPdenovo2: an empirically improved memory-efficient short-read de novo assembler. Gigascience (2012) 20.89
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
The sequence and de novo assembly of the giant panda genome. Nature (2009) 15.76
Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet (2007) 15.46
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med (2002) 14.01
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood (2004) 11.07
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A (2004) 10.47
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell (2003) 9.81
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature (2008) 8.38
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest (2003) 8.34
Hypothalamic regulation of sleep and circadian rhythms. Nature (2005) 8.23
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res (2003) 8.06
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science (2012) 7.94
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Ancient human genome sequence of an extinct Palaeo-Eskimo. Nature (2010) 7.51
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol (2002) 7.44
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature (2011) 7.03
Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell (2011) 7.03
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell (2010) 6.33
Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity (2012) 6.29
von Hippel-Lindau disease. Lancet (2003) 6.20
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90
Comment on "The consensus coding sequences of human breast and colorectal cancers". Science (2007) 5.88
Altered microRNA expression in human heart disease. Physiol Genomics (2007) 5.64
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev (2006) 5.53
Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med (2011) 5.24
Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev (2009) 5.21
Superoxide reacts with hydroethidine but forms a fluorescent product that is distinctly different from ethidium: potential implications in intracellular fluorescence detection of superoxide. Free Radic Biol Med (2003) 5.14
Sleep state switching. Neuron (2010) 4.94
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell (2006) 4.52
Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A (2006) 4.51
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell (2004) 4.38
GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev (2009) 4.21
Assemblathon 2: evaluating de novo methods of genome assembly in three vertebrate species. Gigascience (2013) 4.11
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med (2011) 4.10
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A (2007) 4.05
An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest (2004) 4.03
Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell (2009) 4.02
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell (2006) 3.93
MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell (2008) 3.84
Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nat Genet (2004) 3.84
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75
Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell (2002) 3.72
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal (2007) 3.49
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol (2004) 3.40
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A (2003) 3.34
Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell (2006) 3.29
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell (2002) 3.27
Practice patterns in choice of left double-lumen tube size for thoracic surgery. Anesth Analg (2008) 3.25